Related references
Note: Only part of the references are listed.Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
A. Quintas-Cardama et al.
LEUKEMIA (2011)
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
Jianting Long et al.
BLOOD (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Elevated FOSB-expression; a potential marker of valproate sensitivity in AML
Farhat L. Khanim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines
Therese Bredholt et al.
MOLECULAR CANCER (2009)
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid
Anita Ryningen et al.
LEUKEMIA RESEARCH (2009)
A dual role of p53 in the control of autophagy
Ezgi Tasdemir et al.
AUTOPHAGY (2008)
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence
Kensuke Kumamoto et al.
CANCER RESEARCH (2008)
Oral valproic acid for epilepsy -: long-term experience in therapy and side effects
Thorsten Gerstner et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains
Alice Agliano et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
L. Gu et al.
LEUKEMIA (2008)
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Jacob Laubach et al.
ONCOLOGIST (2008)
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
Ranjan Chrisanthar et al.
PLOS ONE (2008)
Valproic Acid and All-Trans Retinoic Acid: Meta-Analysis of a Palliative Treatment Regimen in AML and MDS Patients
Frauke Bellos et al.
ONKOLOGIE (2008)
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
L. M. S. Lau et al.
ONCOGENE (2008)
p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo - New hope for treating aggressive viral lymphomas
Grzegorz Sarek et al.
CELL CYCLE (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
R. A. Blaheta et al.
BRITISH JOURNAL OF CANCER (2007)
Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells
Line Wergeland et al.
MOLECULAR CANCER (2007)
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
Gesine Bug et al.
HAEMATOLOGICA (2007)
Histone deacetylase inhibitors in cancer treatment:: A review of the clinical toxicity and the modulation of gene expression in cancer cells
O. Bruserud et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2007)
MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin
Baoli Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
DJ Pearce et al.
BLOOD (2006)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Autophagy: Dual roles in life and death?
EH Baehrecke
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Animal models of acute myelogenous leukaemia - development, application and future perspectives
E Mc Cormack et al.
LEUKEMIA (2005)
Multicomponent therapeutics for networked systems
CT Keith et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Epigenetic targets in hematopoietic malignancies
R Claus et al.
ONCOGENE (2003)
Acetylation of p53 inhibits its ubiquitination by Mdm2
MY Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation
A Ito et al.
EMBO JOURNAL (2002)
Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways
R Kawagoe et al.
LEUKEMIA RESEARCH (2002)
Share Paper
